Anavex Life Sciences Corp.
Simbols: AVXL
NASDAQ
3.85
USDTirgus cena šodien
-7.3224
P/E koeficients
-2.2699
PEG koeficients
311.23M
MRK Cap
- 0.00%
DIV ienesīgums
Anavex Life Sciences Corp. (AVXL) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 13.16 | 2.7 | 3.2 | 9.1 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 3.22 | 0.7 | 0.4 | 0.4 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 3.36 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-assets | 8713.08 | 3.4 | 3546.7 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.account-payables | 19.05 | 4.3 | 3.8 | 4.7 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 27.39 | 7.3 | 5.9 | 5.6 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12823.08 | 7.3 | 4.3 | 5.6 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | -12823.08 | -7.3 | -4.3 | -5.6 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-liab | 50.11 | 12.5 | 10.2 | 10.8 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0.33 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | -1149.33 | -293.1 | -245.6 | -197.6 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1718.35 | 434.8 | 388 | 348.3 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 619.45 | 154.4 | 152.7 | 161.6 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 569.35 | 141.9 | 142.5 | 150.8 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 619.45 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-debt | -603.07 | -151 | -149.2 | -152.1 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -43.16 | -47.5 | -48 | -37.9 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 13.31 | 16.4 | 18.4 | 8.2 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | -0.31 | 2.5 | 5.4 | -0.7 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0.55 | 0.5 | 5.9 | -4.3 | ||||||||||||||||||||
cash-flows.row.inventory | -1.53 | -0.5 | -5.9 | 4.3 | ||||||||||||||||||||
cash-flows.row.account-payables | -1 | 0.5 | -0.9 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 1.67 | 2 | 6.3 | -1.5 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0.84 | 0.8 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -29.31 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 27.93 | 27.9 | 21 | 153.2 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 1.52 | 1.8 | 0.3 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 29.45 | 29.7 | 21.3 | 153.2 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0.14 | 1.9 | -2.9 | 122.9 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 603.07 | 151 | 149.2 | 152.1 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 602.93 | 149.2 | 152.1 | 29.2 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | -29.31 | -27.8 | -24.2 | -30.4 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 40.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 11.33 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 51.67 | 55.8 | 51 | 41.9 | ||||||||||||||||||||
income-statement-row.row.interest-income | 7.26 | 6.5 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 2.58 | 2.7 | 3.3 | -0.1 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 2.83 | 2.7 | 6.8 | 4.3 | ||||||||||||||||||||
income-statement-row.row.interest-expense | -1.13 | 1 | 0.9 | 0 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 2.23 | 0 | 4.3 | 0.2 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | -46.68 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | -48.91 | -47.5 | -54.4 | -41.9 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | -43.04 | -47.5 | -47.6 | -37.6 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.11 | 0 | 0.4 | 0.3 | ||||||||||||||||||||
income-statement-row.row.net-income | -43.16 | -47.5 | -48 | -37.9 |
Biežāk uzdotie jautājumi
Kas ir Anavex Life Sciences Corp. (AVXL) kopējie aktīvi?
Anavex Life Sciences Corp. (AVXL) kopējie aktīvi ir 154386000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.000.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.357.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.000.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.000.
Kāda ir Anavex Life Sciences Corp. (AVXL) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -47491000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 0.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 55756000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 143765000.000.